Author

B. Wingelhofer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell signaling & trafficking· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:ATAC-seq· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

R. Moriggl· 3 shared A. Orlova· 2 shared C. Bock· 2 shared D. Stoiber· 2 shared F. Aberger· 2 shared J. Horvath· 2 shared S. Kubicek· 2 shared V. Poli· 2 shared

Activity by Year

2018-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

R. Moriggl

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

STAT3 restricts prostate cancer metastasis and antiandrogen resistance by controlling LKB1/CREB signaling pathway

J. Pencik, C. Philippe, M. Schlederer, M. Pecoraro, S. Grund-Groeschke, W. J. Li, A. Tracz, I. Heidegger, S. Lagger, K. Trachtova, M. Oberhuber, E. Heitzer, O. Osman, H. A. Neubauer, B. Wingelhofer, , C. McKinney

This study identifies STAT3's role in restricting prostate cancer metastasis and antiandrogen resistance by regulating the LKB1/CREB signaling pathway in mouse models and human patients.

bioRxiv · Aug 25, 2022 · PreprintCancer Biology

STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pigmentation pathway

A. Swoboda, R. Soukup, K. Kinslechner, B. Wingelhofer, D. Schoerghofer, C. Sternberg, H. Pham, M. Vallianou, J. Horvath, D. Stoiber, L. Kenner, L. Larue, V. Poli, F. Beermann, T. Yokota, , R. Moriggl

This study shows that STAT3 promotes melanoma metastasis by repressing the MITF pigmentation pathway through CEBP induction.

Oncogene · Dec 15, 2020Peer-reviewedCancer Biology

The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease

L. Kosack, B. Wingelhofer, A. Popa, B. Vilagos, A. Orlova, P. Majek, K. Parapatics, A. Lercher, B. Agerer, A. Ringler, J. Klughammer, M. Smyth, K. Khamina, H. Baazim, D. A. Rosa, , A. Bergthaler

This study identifies the ERBB-STAT3 axis as a driver of Tasmanian devil facial tumor disease and proposes a dual chemo-immunotherapeutic strategy.

bioRxiv · Apr 12, 2018Cancer Biology